Literature DB >> 23301733

JAKs and STATs in immunity, immunodeficiency, and cancer.

John J O'Shea1, Steven M Holland, Louis M Staudt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23301733      PMCID： PMC7604876          DOI： 10.1056/NEJMra1202117

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  99 in total

1.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.

Authors:  Manuel Montesinos-Rongen; Elzbieta Godlewska; Anna Brunn; Otmar D Wiestler; Reiner Siebert; Martina Deckert
Journal:  Acta Neuropathol       Date:  2011-10-22       Impact factor: 17.088

2.  Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival.

Authors:  M G Hunter; B R Avalos
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Authors:  Francisco J Hernandez-Ilizaliturri; George Deeb; Pier L Zinzani; Stefano A Pileri; Farhana Malik; William R Macon; Andre Goy; Thomas E Witzig; Myron S Czuczman
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

4.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

5.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

6.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

7.  A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory.

Authors:  Andrea M Siegel; Jennifer Heimall; Alexandra F Freeman; Amy P Hsu; Erica Brittain; Jason M Brenchley; Daniel C Douek; Gary H Fahle; Jeffrey I Cohen; Steven M Holland; Joshua D Milner
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

8.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

Authors:  A Scuto; P Krejci; L Popplewell; J Wu; Y Wang; M Kujawski; C Kowolik; H Xin; L Chen; Y Wang; L Kretzner; H Yu; W R Wilcox; Y Yen; S Forman; R Jove
Journal:  Leukemia       Date:  2010-12-17       Impact factor: 11.528

9.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

10.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069
View more
  272 in total

1.  Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity.

Authors:  Claudia Mertens; Bhagwattie Haripal; Sebastian Klinge; James E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

2.  Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.

Authors:  Patricia A Toniolo; Suhu Liu; Jennifer E Yeh; Pedro M Moraes-Vieira; Sarah R Walker; Vida Vafaizadeh; José Alexandre M Barbuto; David A Frank
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

3.  Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.

Authors:  Maria-Elena Liosi; Stefan G Krimmer; Ana S Newton; Thomas K Dawson; David E Puleo; Kara J Cutrona; Yoshihisa Suzuki; Joseph Schlessinger; William L Jorgensen
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

Review 4.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 5.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

6.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.

Authors:  David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 8.  Emerging cell and cytokine targets in rheumatoid arthritis.

Authors:  Gerd R Burmester; Eugen Feist; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

9.  Short peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections.

Authors:  Chulbul M Ahmed; Howard M Johnson
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

10.  A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling.

Authors:  Ronald Bozeman; Erika L Abel; Everardo Macias; Tianyi Cheng; Linda Beltran; John DiGiovanni
Journal:  Mol Carcinog       Date:  2014-01-25       Impact factor: 4.784
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.